Goldman Sachs has initiated coverage on medical equipment maker ResMed and biotech giant CSL with a ‘buy’ ratings as analysts ...

The note reveals that Goldman has initiated coverage with a buy rating and $48.90 price target on ResMed's shares. Based on ...

Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

Based in San Diego, California, ResMed Inc. (RMD) develops, manufactures, distributes, and markets medical devices and ...

RMD's shares gain on the back of robust mask and device sales growth. However, the unfavorable macroeconomic scenario is ...

Rebecca Dancer is a full-time writer living in Los Angeles. She writes for a variety of publications, covering everything from beauty and wellness to fashion and lifestyle. Taylor has been an ...

These devices reach levels that can't be tapped by creams and serums. Daley Quinn is a full-time journalist, editor, copywriter, and content creator covering beauty, wellness, health, and ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

ResMed, Inc. holds a major position as designer, manufacturer, as well as a distributor in the worldwide market for generators, masks, and related accessories for the treatment of sleep-disordered ...

Intricate linen masks were central to theater performances in ancient Greece. Credit: Carole Raddato, CC BY-SA 2.0 One of the most enduring art forms from ancient Greece is that of theater. Greek ...

Imagine looking at your selfie and finding a number that represents your biological age — finding out how old your body feels, rather than what the calendar says. This interesting concept, known as ...